Literature DB >> 29528400

The Management of Intestinal Penetrating Crohn's Disease.

Robert P Hirten1, Shailja Shah1, David B Sachar1, Jean-Frederic Colombel1.   

Abstract

Crohn's disease (CD) leads to the development of complications through progressive uncontrolled inflammation and the transmural involvement of the bowel wall. Most of the available literature on penetrating CD focuses on the perianal phenotype. The management of nonperianal penetrating complications poses its own set of challenges and can result in significant morbidity and an increased risk of mortality. Few controlled trials have been published evaluating this subgroup of patients for clinicians to use for guidance. Utilizing the available evidence, we review the epidemiology, presentation, and modalities used to diagnosis and assess intestinal fistulas, phlegmons, and abscesses. The literature regarding the medical, endoscopic, and surgical management options are reviewed providing physicians with a therapeutic framework to comprehensively treat these nonperianal penetrating complications. Through a multidisciplinary evidence-based approach to the complex sequela of CD outcomes can be improved and patient's quality of life enhanced.10.1093/ibd/izx108_video1izx108_Video5754037501001.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29528400     DOI: 10.1093/ibd/izx108

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  7 in total

1.  Early Anti-Tumor-Necrosis-Factor Therapy for Crohn's Disease-Related Abdominal Abscesses and Phlegmon in Children.

Authors:  Brad D Constant; Edwin F de Zoeten; Jason P Weinman; Lindsey Albenberg; Frank I Scott
Journal:  Dig Dis Sci       Date:  2022-07-05       Impact factor: 3.487

Review 2.  The Optimal Management of Fistulizing Crohn's Disease: Evidence beyond Randomized Clinical Trials.

Authors:  Panu Wetwittayakhlang; Alex Al Khoury; Gustavo Drügg Hahn; Peter Laszlo Lakatos
Journal:  J Clin Med       Date:  2022-05-28       Impact factor: 4.964

3.  Total flavone of Abelmoschus manihot suppresses epithelial-mesenchymal transition via interfering transforming growth factor-β1 signaling in Crohn's disease intestinal fibrosis.

Authors:  Bo-Lin Yang; Ping Zhu; You-Ran Li; Min-Min Xu; Hao Wang; Li-Chao Qiao; Hai-Xia Xu; Hong-Jin Chen
Journal:  World J Gastroenterol       Date:  2018-08-14       Impact factor: 5.742

4.  Crohn's disease: prevalence, MR features, and clinical significance of enteric and colonic sinus tracts.

Authors:  Martina Scharitzer; Bernd Koizar; Harald Vogelsang; Michael Bergmann; Christian Primas; Michael Weber; Wolfgang Schima; Thomas Mang
Journal:  Eur Radiol       Date:  2020-05-26       Impact factor: 5.315

5.  Serum exosomal microRNA-144-3p: a promising biomarker for monitoring Crohn's disease.

Authors:  Peng Chen; Shanshan Huang; Qiao Yu; Kang Chao; Ying Wang; Gaoshi Zhou; Xiaojun Zhuang; Zhirong Zeng; Minhu Chen; Shenghong Zhang
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-12-23

6.  Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn's Disease.

Authors:  Marta S Alexdottir; Arno R Bourgonje; Morten A Karsdal; Martin Pehrsson; Roberta Loveikyte; Hendrik M van Dullemen; Marijn C Visschedijk; Eleonora A M Festen; Rinse K Weersma; Klaas Nico Faber; Gerard Dijkstra; Joachim H Mortensen
Journal:  Front Med (Lausanne)       Date:  2022-07-12

7.  Perianal and Luminal Relapse Following Perianal Surgical Intervention in Crohn's Disease.

Authors:  Hejun Zhou; Xuehong Wang; Feihong Deng; Pianpian Xia; Zengrong Wu
Journal:  Int J Gen Med       Date:  2021-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.